Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
ODDITY TECH 0CDI.PA-O 0META 11.03MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,233.66
-13.27 (1.06%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
220 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Eli Lilly & Co. (LLY) is recognized as a leading player in the healthcare industry, particularly in the GLP-1 drug market, which has driven significant stock performance, up approximately 370% over the past five years. Experts highlight the company’s robust drug pipeline, strong execution, and expansion plans, particularly with the anticipated oral version of its weight-loss drug. Despite these strengths, many analysts warn about current high valuations, suggesting that the stock may be priced to perfection, creating caution around new investments at present levels. While the company has a diversified portfolio beyond GLP-1 drugs, stock performance has recently hit all-time highs, prompting some to advise a strategic wait for pullbacks before making new purchases. Overall, analysts see a positive growth trajectory for Eli Lilly in terms of revenue and earnings, backed by a strong market position and effective management of its drug offerings.

consensus icon
Consensus
Positive
valuation icon
Valuation
Overvalued
review icon
Similar
Amgen,AMGN
BUY

Eli Lilly & Co.(LLY)

Feb 22, 2021
A fave of his, up 19% YTD. Last month they delivered a terrific quarter and strong phase 2 data on their Alzheimer's drug, a possible game-changer. They also have a Covid antibody treatment that's already selling well. Most recentlty they delivered good phase 3 trial results on their cholesterol, weighr-loss drug for diabetes.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$200.68

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
RISKY

Eli Lilly & Co.(LLY)

Feb 16, 2021
Allan Tong’s Discover Picks LLY stock is now flirting with 52-week highs and trading above its 50- and 200-day moving averages. It trades at 25.55x and pays a 1.64% dividend. Essentially, positive news on March 12 will launch the LLY stock—and alleviate the suffering of many people and their families—but negative headlines will sink it, which might make it an even bigger bargain stock. Read 3 Bargain Stocks: Eli Lilly, Unilever & Apple for our full analysis.
Photo of Stockchase DiscoverStockchase Discover
Owned
Unlock Rating
$205.76

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Feb 11, 2021
Recent great results on phase 2 of Alzheimer's testing. There will be a lot of focus on the results around March 12. It it works, tremendous upside. Huge for families and for LLY. Diabetes franchise is performing extremely well. Oncology is building out.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$202.12

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Eli Lilly & Co.(LLY)

Jan 22, 2021
Their stock has rallied so much after vaccine hopes that it's now cooling off. Their pipeline of drugs is super. Any further positive news about their Alzheimer's drug push this stock higher.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$206.14

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Oct 19, 2020
He owns a basket. He owns this one for their oncology division. He has not owned it for anything COVID-related. Sometimes it is better to buy a basket of these companies.
Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$143.86

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Sep 21, 2020
They just released very promising data on their breast cancer drug (the previous update in June saw the stock pop), but the stock still dropped in price today. This is strange and undeserved, but the selling won't last.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$151.18

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 02, 2019
He sold it several months ago, because it outperformed like crazy in late-2018. That was expected, because healthcare is the most defensive sector and Q4 was a bear market with fears of a recession. LLY made an acquisition in oncology and one of their big drugs got withdrawn. Novo Nordisk may launch a diabetes drug in September to fcompete with LLY.
Photo of David FingoldDavid Fingold
No
Unlock Rating
$111.60

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Jul 08, 2019
It has one of the best growth profiles on the street with EPS growth at 10%. It trades at a premium to its peers, though. They have some potential blockbuster drugs focused on diabetes and heart disease. Itt depends on the effectiveness of that drug. Now is a good entry point. (Analysts’ price target is $125.81)
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$111.52

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 30, 2019
The whole drug industry is a slow growth one. It is difficult to get top line growth. That growth tends to come from a revolving set of assets. MRK-N has a bit of a leg up and is growing rapidly. It has a long runway before patent expiration. He prefers MRK-N.
Photo of Gordon ReidGordon ReidUnlock Rating
$115.90

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Eli Lilly & Co.(LLY)

May 03, 2019
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$116.97

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Eli Lilly & Co.(LLY)

Apr 15, 2019
(A Top Pick Dec 18/18, Up 17%) He owned a lot in this sector and sold on strength. He would have no problem buying it if he did not have a healthcare stock. It is one of the few areas that are truly in a secular bull market.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
No
Unlock Rating
$124.08

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

Apr 08, 2019
He is not yet taking profits. They dominate the insulin business. As the world gets larger and overeats … The stock takes patience. It will probably sell off with the market.
Photo of Bruce MurrayBruce Murray
Owned
Unlock Rating
$127.13

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Eli Lilly & Co.(LLY)

Mar 22, 2019
What does the increase in volume signal? Some technicians see volume as confirmation. You need volume spike to confirm a move. On the downside, volume doesn't tell you a lot, as things can start slowly. So don't read too much into it. If this stock comes back down to north of $105, a lot of investors would probably come back in. A good name, if you didn't want to buy XLD or HHL.T.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$128.30

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Dec 18, 2018
Broke out over the summer. Healthcare is one of the few sectors that's in a secular bull market, and is even making new highs in the current bull market. LLY tends to beat guidance. They deliver. This trend should continue into 2019. (Analysts’ price target is $114.96)
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$106.50

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Oct 18, 2018

Just bought it. They have come with new pills for diabetes with huge potential. Yield of 2.0%. Drugs stocks are in favor. Likes the sector.

Photo of Bruce MurrayBruce Murray
Owned
Unlock Rating
$113.31

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 166 to 180 of 212 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ATD.TO -0.8$85.19
1523.HK 0$
CSU.TO -20.01$3078.66
NVO 1.74$48.66
PAYC 2.08$231.7

Today's Top Picks

ODDITY T… 0$
CDI.PA-O 0$
META 11.03$570.05
MNT.TO 0.69$69.95
COPX 1.79$96.32

Popular Articles

Latest Sell Signals

ORCL 2.31$144.76
GAW-LSE 0$
BB.TO 0.17$10.79
SHOP.TO 5.21$212.84
IBM 3.15$234.19

Most Recent Experts

Jason Del Vicario

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like